Case Report

Identification of IVS-I (-1) (G > C) or Hb Monroe as a Report on the Beta-globin Gene with a Beta-thalassemia Minor Phenotype in South of Iran

Mohammad Hamid PhD•1.2, Gholamreza Shariati PhD2.3, Alihossein Saberi PhD2.3, Bijan Kaikhaei MD2.4, Hamid Galehdari PhD3.4, Marziye Mohammadi-Anaei BSc²

Abstract

We described the first report of IVS-I (-1), codon 30 (G > C) or Hb Monroe in five individuals from four unrelated families in Khuzestan Province. Polymerase chain reaction (PCR) followed by sequencing of the beta-globin gene confirmed the presence of Hb Monroe in the heterozygous form which causes beta-thalassemia due to missplicing in the course of mRNA processing. This mutation has been described in individuals originated from Arabic and Behbahani origins, Ahvaz City, south of Iran. The knowledge of the beta-globin variants present in the Iranian population is essential for the molecular diagnosis and prevention of hemoglobinopathies.

Keywords: Beta-globin gene, Iran, thalassemia (thal)

Cite this article as: Hamid M, Shariati G, Hossein Saberi A, Kaikhaei B, Galehdari H, Mohammadi-Anaei M. Identification of IVS-I (-1) (G > C) or Hb Monroe as a report on the beta- globin gene with a beta- thalassemia minor phenotype in south of Iran. Arch Iran Med. 2013; 16(9): 563 – 564.

Introduction

eta-thalassemia (β-thal) syndrome is one of the most frequent hereditary diseases in the Mediterranean region, comprising about 280 mutations. 1 These mutations lead to reduction (β^+ type) or absence (β° type) of β -globin chain production, resulting in β -thal phenotype. The majority of β -thal mutations are point mutations and rarely are microinsertion/deletion.² Hb Monroe results from a splice site point mutation (G > C) in the last nucleotide of β - globin exon 1, which is also the penultimate nucleotide of codon 30 of the β - globin peptide (AGG- > ACG; Arg-> Thr). This mutation as β° type mutation prevents splicing completely and no normal mRNA is formed.

We here describe the first report of IVS-I (-1), codon 30 (G > C)or Hb Monroe in five individuals from four unrelated families in Khuzestan Province.

Materials and Methods

This study included individuals referred to the Narges Prenatal Diagnostics and Medical Genetics Laboratory during the one year for carrier detection as part of a national program for the prevention of thalassemia.

Analysis of red blood cell indices and Hb analysis were carried out according to standard methods. Following obtaining written informed consent, molecular studies were conducted on genomic DNA isolated from peripheral blood cells by a salting-out procedure. For identifying α-thal genotype, investigation of common

Authors' affiliations: Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran, 2Narges Medical Genetics and PND Laboratory, Ahvaz, Iran, 3Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁴Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

•Corresponding author and reprints: Mohammad Hamid PhD, Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran13164, Iran. Tel: +98 2166480780, Fax: +98 2166480780, E-mail: hamid143@yahoo.com.

Accepted for publication: 28 May 2013

Mediterranean α-globin gene deletions was performed by Gap-PCR as described elsewhere. 4 Beta- globin genes were amplified and directly sequenced by the chain termination method on an ABI-3130 (Applied Biosystems, Foster City, CA, USA).

Results

In this study, we described the first report of IVS-I (-1), codon 30 (G > C) or Hb Monroe in five individuals from four unrealated families in Khuzestan Province. They were referred to the Laboratory for carrier detection as part of a national program for the prevention of thalassemia with mild anemia, microcytosis, and hypochromia. The hematologic and molecular data of the study subjects are summarized in Table 1. Hb X has not been found in these cases by a cellulose acetate electrophoresis, so it is an unstable hemoglobin variant. Sequencing chromatograms of this mutation is shown in Figure 1.

Discussion

Hb Monroe was first found in a transfusion-dependent 15-yearold black girl from the USA with the promoter mutation A > G at position -29.5 This mutation was also reported from other populations, such as Indians,⁶ Tunisians,⁷ and Tajiks.⁸ This is the first report of this mutation in south of Iran and second reported in Iranian population. It was reported in a patient from Qazvin Province who inherited this mutation with IVSII-1.9 This missense mutation not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild type allele.3 Therefore, it plays a role in pathogenesis by reducing the splicing efficiency.

In conclusion, Iran as a country with multiethnic groups has different provinces with their own characteristic spectrum of betaglobin gene mutations. Searching for and identifying rare or new mutations is a constant priority in population screening, genetic counseling, and prenatal diagnosis of thalassemia.

Table1. The hematologic and molecular data

Subject	G.Ka	B.Ka	N.Ni	L.Se	A.Se
Age (year)	25	27	22	21	30
Sex	F	M	F	F	M
Hb (g/dL)	11.0	12.3	12.0	8.7	11.0
RBC (1012/L)	5.65	6.71	6.09	4.58	5.91
MCV(fL)	64.4	62.6	64	60.2	68.1
MCH (pg)	19.5	18.3	19.7	19	19.8
MCHC (%)			30.7	31.5	
Hb A (%)	93.8		92.9	93.9	95.1
Hb F (%)	2.6		1	0.8	0.6
Hb A2 (%)	3.6		6.1	5.3	4.3
β-genotype	Hb Monroe/N	Hb Monroe/N	Hb Monroe/N	Hb Monroe/N	Hb Monroe/N
α-genotype	αα/αα	αα/αα	$\alpha^{-3.7}\alpha/\alpha\alpha$	αα/αα	αα/αα
Origin	Behbahani	Behbahani	Arab	Arab	Arab




Figure 1. Sequencing chromatograms of Hb Monroe (G > C) mutation.

References

- Giardine B, van Baal S, Kaimakis P, Riemer C, Miller W, Samara M, et al. Hbvar database of human hemoglobin variants and thalassemia mutations 2007 update. Hum Mutat. 2007; 28: 206.
- Musollino G, Mastrolonardo G, Prezioso R, Pagano L, Primignani P, Carestia C, et al. Molecular mechanisms of a novel beta-thalassemia mutation due to the duplication of tetranucleotide 'agct' at the junction ivs-ii/exon 3. Ann Hematol. 2012; 91: 1695 - 1701.
- Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading NS, et al. Missense mutation of the last nucleotide of exon 1 (G>C) of beta- globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. Haematologica. 2007; 92: 1715 – 1716.
- Akbari MT, Hamid M. Identification of alpha-globin chain variants: A report from Iran. *Arch Iran Med*. 2012;**15:**564 – 567.

- Gonzalez-Redondo JM, Stoming TA, Lanclos KD, Gu YC, Kutlar A, Kutlar F, et al. Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States. Blood. 1988; 72: 1007 - 1014.
- Varawalla NY, Old JM, Sarkar R, Venkatesan R, Weatherall DJ. The spectrum of beta-thalassaemia mutations on the Indian subcontinent: The basis for prenatal diagnosis. *Br J Haematol*. 1991; **78**: 242 – 247. Fattoum S, Guemira F, Oner C, Oner R, Li HW, Kutlar F, et al.Beta-
- thalassemia, Hb s-beta-thalassemia, and sickle cell anemia among Tunisians. Hemoglobin. 1991; 15: 11 - 21.
- Fedorov AN, Nasyrova F, Smirnova EA, Bocharova TN, Limborska SA. Ivs-i-1 (g-->c) in combination with -42 (c-->g) in the promoter region of the beta-globin gene in patients from Tajikistan. Hemoglobin. 1993; **17:** 275 – 278.
- Sarookhani MR, Ahmadi MH. Rare and unexpected beta-thalassemic mutations in Qazvin Province of Iran. African Journal of Biotech. 2010; **9:** 95 – 101.